No grade 2 or higher neuropathy
Patients with grade 2 or higher peripheral neuropathy will be excluded in the dose escalation phase of the protocol
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patients must not have grade 3 or higher peripheral neuropathy
ELIGIBILITY CRITERIA - PHASE II (ARM D): Patients must not have grade 3 or higher peripheral neuropathy
Patients with peripheral neuropathy of grade 2 or higher
Grade 2 or higher peripheral neuropathy at screening
Grade 1 or higher CNS hemorrhage on baseline brain MRI, or history of grade 2 or higher CNS hemorrhage within 12 months
Uncontrolled Grade 3 or higher infection
Grade 2 or higher peripheral neuropathy or ataxia per NCI CTCAE
Active esophagitis grade B or higher
Patients with grade 2 or higher neuropathy
Patients must not have Grade 2 or higher peripheral neuropathy.
Grade 2 or higher pneumonitis
Grade 3 or higher peripheral neuropathy
No symptoms attributable to grade 2 or higher peripheral neuropathy
Patients with grade 2 or higher peripheral neuropathy are excluded
CTCAE grade 3 or higher peripheral neuropathy
Patients with persistent grade 3 or higher prior vincristine (VCR) (vincristine sulfate)-related neuropathy
Current grade 2 or higher peripheral neuropathy
Grade 2 or higher peripheral neuropathy.
More than one grade 2 or higher transaminase elevation
Patients with grade 2 or higher peripheral neuropathy
participants with Grade 2 or higher residual toxicities from prior therapy (including Grade 2 or higher peripheral neuropathy or any grade neuropathy with pain; excluding alopecia). This includes recovery from any major surgery. Note: Participants with planned surgical to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery.
Grade 2 or higher persisting prior treatment-related neuropathy
Grade 2 or higher peripheral neuropathy
Paclitaxel arm: grade 2 or higher neuropathy
Grade 2 or higher peripheral neuropathy.
Grade 2 or higher peripheral neuropathy per NCI CTCAE
Grade 2 or higher peripheral neuropathy
Patients must not have grade 2 or higher peripheral neuropathy
Active Grade 3 or higher infection.
Patients who have had grade 2 or higher peripheral neuropathy within 14 days prior to registration are not eligible (must have resolved to grade 1 or lower to register)
Peripheral neuropathy or neuropathic pain Grade 2 or higher
Neuropathy grade 2 or higher
Grade 2 or higher peripheral neuropathy (paclitaxel arm only)
Grade 2 or higher neuropathy (CTCAE V4.0)
Subjects with T3 or higher, and N3 disease
Current grade II or higher peripheral neuropathy.
Significant peripheral neuropathy defined as grade 2 or higher
Current grade II or higher peripheral neuropathy.
Peripheral neuropathy that is grade 2 or higher
Grade 3 or higher peripheral neuropathy
Grade 2 or higher peripheral neuropathy per NCI CTCAE
Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days prior to Day 1
Grade 2 or higher neuropathy
Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days prior to the first dose of study drug
Current grade 3 or higher neuropathy
Grade 2 or higher peripheral neuropathy
Grade 2 or higher peripheral neuropathy at the time of study entry
Grade 2 or higher oral mucositis
Grade 2 or higher peripheral neuropathy
Grade II or higher neuropathy
Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days of first dose of study drug
